Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T5UL
|
|||
| Former ID |
DAP001147
|
|||
| Drug Name |
Benzphetamine
|
|||
| Synonyms |
Benzaphetamine; Benzfetamina; Benzfetamine; Benzfetaminum; Benzofetamina; Benzphetaminum; Benzylamphetamine; Benzfetamina [DCIT]; Benzfetamina [Spanish]; Benzfetaminum [Latin]; U 0441; Benzfetamina [INN-Spanish]; Benzfetamine (INN); Benzfetamine [INN:BAN]; Benzfetaminum [INN-Latin]; Benzofetamina [INN-Spanish]; Benzphetaminum [INN-Latin]; D-Benzphetamine; Didrex (TN); N-Benzylmethamphetamin; N-Benzyl-N,alpha-dimethylphenethylamine; N,alpha-Dimethyl-N-(phenylmethyl)benzeneethanamine; D-N-Methyl-N-benzyl-beta-phenylisopropylamine; N,alpha-Dimethyl-N-(phenylmethyl)-benzeneethanamine; N-Benzyl-N-methyl-1-phenyl-2-propanamine; N-benzyl-N-methyl-1-phenylpropan-2-amine; N-methyl-1-phenyl-N-(phenylmethyl)propan-2-amine; Benzeneethanamine, N,alpha-dimethyl-N-(phenylmethyl)-, (+)-(9CI); (+)-N,alpha-dimethyl-N-(phenylmethyl)-benzeneethanamine; (+)-N-benzyl-N,alpha-dimethylphenethylamine; (+)-benzphetamine; (2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine; (R,S)-N-Benzyl-alpha,N-dimethylphenethylamin; (S)-(+)-N-benzyl-N,alpha-dimethylphenethylamine; (S)-(+)-benzphetamine; (S)-benzphetamine; (alphaS)-N,alpha-dimethylphenethylamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66] | Approved | [1] | |
| Company |
Pharmacia
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H21N
|
|||
| Canonical SMILES |
CC(CC1=CC=CC=C1)N(C)CC2=CC=CC=C2
|
|||
| InChI |
1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1
|
|||
| InChIKey |
YXKTVDFXDRQTKV-HNNXBMFYSA-N
|
|||
| CAS Number |
CAS 156-08-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:3044
|
|||
| ADReCS Drug ID | BADD_D00242 ; BADD_D00243 ; BADD_D00249 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | N-methyl-D-aspartate receptor (NMDAR) | Target Info | Antagonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.